




Available online on 15 Dec, 2022 at <https://ijdra.com/index.php/journal>

## International Journal of Drug Regulatory Affairs

Published by Diva Enterprises Pvt. Ltd., New Delhi  
Associated with Delhi Pharmaceutical Sciences & Research University  
Copyright© 2013-22 IJDRA



### Review Article

Open Access

## A study of Regulatory aspects on Registration of Orphan Drugs in US and EU

S. Vasantha Mounika, P. Ramya, M.S.L. Divya, S. Naga Swaroopa, K. Venkateswara Raju\*, N.L. Prasanthi

Department of Pharmaceutical Regulatory Affairs, Shri Vishnu College of Pharmacy (Autonomous), Vishnupur, Bhimavaram-534202, Andhra Pradesh, India.

### Abstract

The medicinal products used in the treatment, prevention, and diagnosis of rare disease like Myoclonus disease, Huntington's disease, Tourette syndrome are called as Orphan drugs, when it comes to defining rare disease and approving them as "Orphan designations." The Criteria varies from country to country based on severity, prevalence of the disease and alternative therapies available.

In 1983, the US government brought the Orphan Drug Act to facilitate and encourage pharmaceutical company to develop orphan drugs without which they show reduced interest in the research and development of these drugs. The reason being their low market value and sales of orphan a drug is so miniscule that it will not enable them to even recover a fraction of the investment made in them.

After the inception of "Orphan Drugs" act 4500 orphan designations have been approved, 730 biologic drug products have been approved to treat 250 Orphan designations.

In the past decades, orphan designations have doubled in number when compared to its preceding decade but only 1/5th of the developed medications to treat them and received regulatory approval.

**Keywords:** Orphan drugs, rare disease, orphan designations, world health organization, food and drug administration, European medicinal agency

**Article Info:** Received 10 Nov. 2022; Review Completed 11 Dec. 2022; Accepted 14 Dec. 2022



### Cite this article as:

Mounika SV, Ramya P, Divya MSL, Swaroopa SN, Raju KV, Prasanthi NL. A study of Regulatory aspects on Registration of Orphan Drugs in US and EU. Int J Drug Reg Affairs [Internet]. 2022 Dec 15 [cited 2022 Dec 15]; 10(4):45-52. Available from: <http://ijdra.com/index.php/journal/article/view/563>

DOI: 10.22270/ijdra.v10i4.563

\*Corresponding author

### 1. Introduction

Drugs are pharmaceuticals used for the evaluation diagnosis or medication of rare often fatal or severely disabling diseases.

The name orphan comes from the Greek word "orphanos," meaning a baby does not have parental care. Rare diseases are sometimes referred to as orphan diseases because no drug manufacturing company was prepared to adopted them. As a result, rare diseases resemble orphan infants who have no parents and have historically necessitated drug development efforts. (1)

A Rare or Orphan condition affects a smaller amount of the people and its causes could or could not be determined by genetics. (2)

As defined by the World Health Organization, rare diseases are diseases or conditions that have a prevalence of less than 1 in 1000 of the population. The NIH classified diseases to be rare disease or condition

when they prevalence in 200,000 people or less in the US. There are primarily two differences between the two definitions. First, in Europe, rare diseases are more commonly defined as diseases or conditions that affect no more than 5 in 10,000 people. Second, according to DSM, the orphan drug designation is made in the United States. (3)

However, in order to provide the best equipment to their people physicians vary their recommendations based on the sort of illness a few of their definitions depend only on the number of individuals coping with a hardship and other considers like the existence of appropriate treatments or the severity of the situation. (4)

*Some of the orphan drugs along with the disease treated:*

- ❖ **OPDIVO:** Bladder Cancer, Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer (NSCLC), and Liver Cancer have all been approved by the FDA.

- ❖ **RITUXAN:** Rituxan is exceptional in that it is authorised for the treatment of autoimmune and cancer conditions such as rheumatoid arthritis, non-Hodgkin's lymph, and chronic lymphocytic leukaemia (CLL).
- ❖ **REVLIMID:** Currently, the FDA has given Revlimid's approval for the treatment of newly diagnosed cases of myelodysplastic syndromes (MDS), multiple myeloma, and patients with multiple myeloma who have undergone autologous hematopoietic stem cell transplantation.

### 1.1 Orphan Drug Act


An orphan drug act that was instituted in the USA in 1983 was world's first law to designate drugs for development purposes. Canada, Australia, Europe, Japan, and Singapore. All have similar laws in place. Canada and Russia are in the process of formulating their laws

the drug act in the USA set up new advantages for sponsors.

Which is intended to improve the options for treatments for rare disorders, this classification only means that the sponsor is eligible for specific advantages during the process of drug development.

Within the United States of America, The OOPD in the FDA grants orphan Designation to any product used for the rare diseases described above. Orphan status can be granted at any time during the drug development procedure. A product designated as an orphan drug can later receive market approval only when clinical study data demonstrate the product's safety and efficacy.

Orphan status confers certain benefits to sponsors; a 50% tax credit on clinical development costs, application fee waivers, grants to conduct clinical trials, and 7 years of market exclusivity.



**Figure 1.** Showing Orphan status confers certain benefits to sponsors

Those Incentives sincerely have a huge effect on orphan drug improvement within the decade earlier than the orphan drug act. Only 10 merchandises for uncommon illnesses received advertising authorization, and more than 10 products have been approved for marketing each year since then, and about 430 products have been approved for rare diseases to date. OOPD additionally administers an associated application designed to inspire the improvement of scientific devices for the treatment or diagnosis of uncommon sicknesses. (5)

## 2. Regulations of Orphan Drug in US

### Definition

In US, a drug or biological product can diagnose as an orphan drug if its far used to prevent treat or diagnose a situation that affects fewer than 200000 patients.

### Criteria for orphan designation status in the United States

For a drug to receive orphan drug status, the following criteria must be met:

- ✓ A drug that has not been accepted before.
- ✓ A drug with a new orphan indication.
- ✓ A drug is shown to be clinically superior to a previously approved drug. (6)

### 2.1 Orphan Drug Review Process in US

#### 2.1.1 Incentives

**Protocol Assistance:** Giving scientific advice to the developers of designated orphan medicines for rare diseases.

**Waived Regulatory Fees:** Giving some exemptions reduces fees while filing NDA for orphan drugs under PDUFA.

**Tax Credit:** Gives a credit of 50% of the clinical testing costs for the development of drugs.

**Clinical development benefits:** The Orphan products were granted funding for clinical trials to advance rare disease research and the development of orphan drugs.

**Seven Years Marketing Exclusivity:** 7-year market exclusivity is decided by using the office of Orphan Product development (OOPD) upon advertising and marketing approval of the drug. (7)




Figure 2. Showing Orphan drug review process in US.

**Orphan drug designation application in US:**

Table 1. Documents Included in the Orphan Designation Application in US

S. no.	Basic elements	Description
1	Administrative information	Descriptive name of the product Manufacturer for drug substance/drug product.
2	Explaining what is the disease or condition	Mechanism of action of drug pathophysiology, Etiology, Treatment options, Prognosis
3	Providing sufficient scientific rationale	Drug description and MOA relevant to disease/condition. in vitro, in vivo, clinical studies data relevant to drug and disease/condition
4	Determining the population estimate to support that the disease is rare.	Foreign, geographically restricted, or old data Registries, databases, literature searches Estimate must be current as of the time of application submission All calculations and references used to derive the population estimate

**USFDA Approved Orphan Drugs -FY 2022**

Table 2. Showing USFDA Approved orphan drugs in 2022

S.no	Generic name	Trade name	Orphan designation	Market approval date
1	Stiripentol	Diacomit	Treatment of Dravet syndrome.	07-14-2022
2	Carfilzomib	Kytrolis	Treatment of multiple myeloma.	06-30-2022
3	Crizotinib	Xalkori	Treatment of inflammatory my fibroblastic tumour.	07-14-2022
4	Lisocabtagene meraleucel	Breyanzi	Treatment of follicular lymphoma	06-24-2022
5	Sodium phenyl butyrate	Pheburane	Treatment of urea cycle disorder	06-17-2022
6	Setmelanotide	Imcivree	Treatment of Bardet- Biedl syndrome	06-16-2022
7	Vutrisiran	Amvuttra	Treatment of transthyretin mediated amyloidosis	06-13-2022
8	Risdiplam	Evrysdi	Treatment of spinal muscular atrophy	05-27-2022
9	Tisagenlecleucel	Kymriah	Treatment of follicular lymphoma	05-27-2022
10	Nivolumab	Opdivo	Treatment of esophageal cancer	05-27-2022
11	Ivosidenib	Tibsovo	Treatment of acute myeloid leukemia.	05-25-2022

S.no	Generic name	Trade name	Orphan designation	Market approval date
12	Treprostinil	Tyvaso dpi	Treatment of pulmonary arterial hypertension	05-23-2022
13	Dupilumab	Dupixent	Treatment of eosinophilic esophagitis	05-20-2022
14	Azecitidine	Vidaza	Treatment of juvenile myelomonocytic leukemia.	05-20-2022
15	Tecovirimat	Tpoxx	Treatment of small pox	05-18-2022
16	Edaravone	Radicava ors	Treatment of amyotrophic lateral sclerosis.	05-12-2022
17	Mavacamten	Camzyos	Treatment of symptomatic hypertrophic cardiomyopathy	04-28-2022
18	Ravulizumab - cwvzs	Ultomiris	Treatment of myasthenia gravis	04-27-2022
19	Alpelisib	Vijoice	Treatment of pik3ca – related overgrowth spectrum.	04-05-2022
20	Axicabtagene ciloleucel	Yescarta	Treatment of follicular lymphoma.	04-01-2022
21	Fen flouramine	Fintepla	Treatment of Lennox – gas taut syndrome.	03-25-2022
22	Sirolimus	Hyftor	Treatment of angiofibroma associated with tuberous sclerosis.	03-22-2022
23	Ciltacabtagene autoleucel	Carvykti	Treatment of multiple myeloma.	02-28-2022
24	Sutimlimab- jome	Enjaymo	Treatment of auto immune haemolytic anemia.	02-04-2022
25	Emtricitabine and tenofovir alafenamide	Descovy	Treatment of HIV -1 infection in pediatric patients under 12 years of age	01-07-2022

### USFDA Approved Orphan Drugs – FY 2021

Table 3. Showing USFDA Approved orphan drugs in 2021. (8)

S.no	Generic Name	Trade Name	Orphan Designation	Marketing Approval Date
1	Voxelotor	Oxbryta	Treatment of sickle cell disease	12/17/2021
2	Efgartigimod alfa-fcab	Vyvgart	Treatment of myasthenia gravis	12/17/2021
3	Carfilzomib	Kyprolis	Treatment of multiple myeloma	11/30/2021
4	Vosoritide	Voxzogo	Treatment of achondroplasia	11/19/2021
5	Asciminib	Scemblix	Treatment of chronic myelogenous leukemia	10/29/2021
6	Coagulation factor IX	Benefix	Treatment of hemophilia B	10-05-2021
7	Maralixibat	Livmarli	Treatment of Alagille syndrome	09/29/2021
8	Ruxolitinib	Jakafi	Treatment of graft versus host disease	09/22/2021
9	Zanubrutinib	Brukinsa	Treatment of splenic marginal zone lymphoma	09/14/2021
10	Ivosidenib	Tibsovo	Treatment of cholangiocarcinoma	08/25/2021
11	Belzutifan	Welireg	Treatment of von Hippel-Lindau disease	08/13/2021
12	Selexipag	Uptravi	Treatment of pulmonary arterial hypertension	07/29/2021
13	Immune globulin intravenous	Octagam 10%	Treatment of dermatomyositis	07/15/2021
14	Cyclosporine	Verkazia	Treatment of vernal keratoconjunctivitis	06/23/2021
15	Posaconazole	Noxafil	Treatment of invasive aspergillosis	06/17/2021
16	Infigratinib	Truseltiq	Treatment of cholangiocarcinoma	05/28/2021
17	Nivolumab	Opdivo	Treatment of esophageal cancer	05/20/2021
18	Nivolumab	Opdivo	Treatment of esophageal cancer	04/16/2021
19	Crotalidae Immune F(ab') <sub>2</sub> (Equine)	Anavip	Treatment of envenomation by Crotaline snakes	04-01-2021
20	Isatuximab-irfc	Sarclisa	Treatment of multiple myeloma	03/31/2021
21	Idecabtagene vicleucel	Abecma	Treatment of multiple myeloma	03/26/2021
22	Casimersen	Amondys 45	Treatment of Duchenne muscular dystrophy	02/25/2021

S.no	Generic Name	Trade Name	Orphan Designation	Marketing Approval Date
23	Umbrisib	Ukoniq	Treatment of splenic marginal zone lymphoma	02-05-2021
24	Carglumic acid	Carbaglu	Treatment of organic acidemias	01/22/2021
25	Crizotinib	Xalkori	Treatment of anaplastic large cell lymphoma	01/14/2021

## 2.2 Case Study

### Withdrawal of Orphan drug designation request for Remdesivir by Gilead:

- ❖ US FDA eliminated orphan medicinal product as an ability covid-19 remedy later complaint that medication covid-19 is a unique disorder changed into “disingenuous”.
- ❖ Gilead Pharmaceuticals requested from the FDA that the classification be removed, allowing the company a longer absolute lifespan instead of 7 to 5 years and significant tax incentives immediately after it was granted.
- ❖ Remdesivir is going to allow virus duplication is a medicine presently being inspected as an ability remedy for covid-19 via numerous clinical tests.
- ❖ Orphan acceptance be a structure plan to encourage the improvement of medication for uncommon condition in which there can be a most effective a small wide variety of human beings fewer than 200 000 humans inside the us that might be treat.
- ❖ Ameet Sar Patwari, a senior lecturer of medicine at Harvard College and the senior supervisor of this device on rule restoration and regulation, stated that the orphan drug act was supposed to enable the improvement of medicines for which there was no real prospect of manufacturing a profit, which is challenging to understand in the case of a treatment for an active pandemic.
- ❖ Tahir Amin declared; Gilead made the right choice in withdrawing the Orphan drug designation status. But it was not supposed to happen in the first place. Because COVID-19 is widespread and will also coexist with other species in our ecosystem, Companies are developing vaccines for ensuring the human beings will be protected. When a vaccine is available, everyone will probably want or need to acquire it.
- ❖ If accepted, Gilead’s remdesivir also may probably end up as a primary line remedy for upcoming flu seasons, so to claim that this is an unprecedented sickness would be to neglect whatever the future holds like if its complete show increases some of the Gilead’s motivation and the FDA’s decision, which makes it appear as though it has been captured.

- ❖ Despite the orphan medication status being dropped, Amin said, Gilead will continue to receive a 5-year exclusivity period for novel molecular entities in addition to the present patent exclusivities that last until at least 2038.
- ❖ Given that now the patent will still be in effect it raises the concern of what the FDA will do with it in the event of a pandemic. (9)

## 3. Orphan Drug Regulations in the European Union

**Definition:** The disorder is taken into consideration to be uncommon if it happens in fewer than five in 10,000 human beings.

The EU gives numerous incentives to inspire organizations inside the studies and development of drugs for uncommon diseases that in any other case would not be developed. Corporations can follow for orphan designation for medicine to access these incentives which meet sure standards proposed by using the EMA.

Although the prevalence of rare diseases is especially low, nearly 27 to 36 million people (or 6% to 8%) of the EU population are affected. Most rare diseases impact children, and nearly 30 percent of them dies before the age of 5. Given these facts, research into the origins and mechanisms of rare diseases and therefore the field of orphan drug development has become increasingly important for the EU Commission and public health organizations.

### Criteria for orphan designation status:

- ❖ Lesser than 5 out of 10000 populate in the EU may have the complication.
- ❖ Medicines must treat prevent or diagnose life-threatening or chronically in capitating conditions if not unlikely that the drug exists doubtful to generate enough revenue to excuse the evolution funding.
- ❖ Where no appropriate diagnostic prophylactic or therapeutic methods exist or where drugs already exist that would provide significant additional benefit to the affected population.


### 3.1 Review Process of Orphan Drugs in Europe

#### 3.1.1 Incentives

- ✓ **Protocol assistance:** A type of medical recommendation unique for distinctive orphan medicines. This permits sponsors to get solutions to their questions about the forms of studies needed to show the medication pleasant benefits and risks and statistics at the vast advantage of the medicine.

- ✓ **10 years of Market exclusivity.** This era of safety is prolonged by means of 2 years for drug treatments that also have complied with an agreed pediatric research plan granted at the time of overview of the orphan medicinal drug designation
- ✓ **Fee reductions:** Organizations applying for specified orphan drug treatments pay decreased

costs for regulatory activities. This includes decreased expenses for protocol assistance, advertising-authorization programs, inspections earlier than authorization packages for modifications to marketing authorizations made after approval and reduced annual expenses



**Figure 3.** Showing Review process of orphan drugs in Europe (10)

- ✓ **Grants:** The organization does no longer provide studies offers for sponsors of orphan drug treatment, but the EU commission and different sources can also provide funding.
- ✓ **Centralized authorization procedure:** All orphan specific medicines are assessed for marketing authorization centrally within the European Union. (11)

The orphan drug designation utility incorporates a briefing report (sections A to E) describing the involved medicinal product, the proposed orphan indication and clinical statistics assisting the orphan drug designation application.

As outlined in Article three of EC law No. 141/2000 an orphan drug designation utility can both be primarily based on the low prevalence and prevalence rate within the European or where an enough return of funding without incentives is questionable.

In both cases, enough information has to be provided which must be presented inside the application following particular regulations as outlined in Article 2 of EC law No 847/2000 and following supportive procedural guidance files provided by way of EMA.

**3.2 Applying for orphan designation**

Applications for medicinal product orphan drug designations should be submitted to EMA in accordance with the procedural guidelines on the structure and substance of orphan drug designation programmes.

From 19 September 2018, candidates want to publish packages for orphan designation and pre- and post-designation activities the usage of EMA's novel comfortable on-line machine IRIS.

**List of documents included in the orphan designation application in EU**

**Table 4.** Showing Documents included in orphan designation application in EU (12)

Sr. no.	List of documents	Description	Format
1	Application form	Administrative information. Sponsor information - Corresponding contact person - OD number	Web form in EMA's online system IRIS.

Sr. no.	List of documents	Description	Format
2	Scientific document: Section A to E	Information on the medicinal product - Proposed orphan drug indication. -Medical information. - Justification of the life-threatening or chronically debilitating nature of the disease. - Data on the prevalence of the condition or disease. - Potential return of investment.	Word/RTF format
3	Proof of establishment of the sponsor in the EU	The sponsor must have a permanent physical address in the European Community.	PDF
4	Translations	Name of the product and the proposed orphan indication translated into all official languages of the European Union, incl. Icelandic and Norwegian	Word
5	References	Scientific articles cited throughout the application as single PDF files	PDF

### 2.3 Number of orphan medicinal products with European Union Designation in Europe




Figure 4. Showing Orphan Medicinal Products approved in EU

## 4. Results and Discussion

### Orphan drugs Comparison in US and EU:

Table 5. Showing Orphan drugs Comparisons in US and EU

S. No	Parameter	US	EU
1	Legal framework	Orphan Drug Act (OAD- 1983) FDA'SOOPD	Commission Regulation EC No 141/ 2000 EMA, COMP
2	Responsible authority prevalence criteria	Fewer than 2,00,000 persons in the US population	Less than 5, in 10,000 persons in the community
3	The review period of the designation procedure	Typically, 90 days	Maximum of 90-days procedure
4	Annual reports	Should be submitted within 14 months after the Orphan drug designation was granted and annually thereafter until marketing approval	Should be submitted within 2 months following the approved designation
5	Protocol assistance	yes	Yes
6	Reduced / waived regulatory fee	yes	Yes
7	Tax credits	50% for clinical studies	Managed by the member state
8	Research grants	Program by NIH and other agencies	"FP6" + National measures
9	Marketing exclusivity	Seven years+ 6 months in case of paediatric exclusivity	Ten years+ 2 years in case of paediatric exclusivity
10	Special approval pathways	Fast-track approval Break through therapy	Accelerated assessment (via PRIME)

S. No	Parameter	US	EU
		Accelerated approval Priority approval	Conditional marketing approval Compassionate use
11	Organization for rare disease	National Organization for Rare Disease (NORD)	European Organization for Rare Disease (EURORDIS)
12	Pricing	Free	Based on member state

## 5. Conclusion

Governments across the globe have supported the development of orphan disease treatments by providing rewards to pharmaceutical companies by incentivizing them through steps like reduction in procedural fees and giving market exclusivity for certain period after approval of marketing authorization.

The main hurdle to maintain orphan designations after getting the marketing authorization approval is in the demonstration of benefits significance over already approved treatment methods.

The no of orphan designation is facing withdraws the reason being failure on the part of sponsor to provide experimental data to confirm his plan which it can avoid by adequate planning at the design phase itself.

Only in a few countries have orphan pharmaceutical initiatives for rare diseases proven successful finding the right incentive structure is challenging in a market with limited first-mover advantages. In addition to the advantages of longer marketing exclusivity periods, waived regulatory fees, subsidies for R&D, tax credits, quick approval, premium pricing, and reduced development times, etc.

Orphan drugs also include challenges like limited scientific knowledge, low number of patient's available, high pricing of these drugs & other regulatory challenges. The ODA's enforcement of more orphan drugs has been developed and approved by the US, and in other countries it has similar legislation.

## Acknowledgements

We would like to express our sincere gratitude to IJDRA Journal for publishing our work.

**Financial Disclosure statement:** The author received no specific funding for this work.

## Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

## References

1. Rana P and Chawla S. Orphan drugs: trends and issues in drug development. *Journal of Basic and Clinical Physiology and Pharmacology*. 2018; 29(5):437-446. <https://doi.org/10.1515/jbcpp-2017-0206>
2. Gautam R & Chauhan I, Verma M, Yasir M. Global orphan drug market: A review. *International Journal of Pharmacology and Pharmaceutical Sciences*. 2015;3(1):25-31.
3. Nagaraja S, H V Raghu Nandan, Vishakante Gowda D and Balamuralidhara V, "A Comparative Study of Orphan Drugs in US, EU & India," March 22 2018, Available from:

<http://www.pharmabiz.com/NewsDetails.aspx?aid=108801&sid=21>.

4. David C. Pryde and Stephen C. Groft, "Chapter 1: Definitions, History and Regulatory Framework for Rare Diseases and Orphan Drugs," in *Orphan Drugs and Rare Diseases*; 2014.p. 3-31, DOI: 10.1039/9781782624202-00003
5. Thaker Z., Jethva K., Bhatt D, Zaveri M and Deshpande S. *Orphan Drugs: Overview and Regulatory Review Process*. *Ijpsr*. 2019; 10(2).505-18 <http://dx.doi.org/10.13040/IJPSR.0975-8232>.
6. *Rare Diseases: Regulatory Incentives for Development of Orphan Drugs - The United States & Europe*. [Internet]. credevo; 2019 Dec [cited 2022 Aug 22]. Available from: <https://credevo.com/articles/2019/12/15/rare-diseases-regulatory-incentives-for-development-of-orphan-drugs-us-europe/>.
7. Jones L. *Orphan Drug Designations in the U.S. and EU* [Internet]. Pro Pharma Group, July 8, 2022 [cited 2022 Aug 20]. Available from: <https://www.propharmagroup.com/blog/orphan-drug-designations-in-the-u-s-and-eu/>.
8. *Search Orphan Drug Designations and Approvals* [Internet]. US FDA; 2022 [cited 2022 Aug 21]. Available from: <https://www.accessdata.fda.gov/scripts/opdlisting/oopd/>.
9. Mahase E. Covid-19: Gilead withdraws orphan drug designation from potential treatment after criticism *BMJ*. 2020; 368 :m1259 doi:10.1136/bmj.m1259
10. *European Medical Agency. Review process of orphan drugs in Europe*. [Internet]. EMEA; 2022 [cited 2022 Aug 20]. Available from: <https://in.images.search.yahoo.com/search/images....>
11. *European Medical Agency Science Medicines Health, Orphan incentives*. [Internet]. EMEA; 2022 [cited 2022 Aug 20]. Available from: <https://www.ema.europa.eu/en/human-regulatory/research-development/orphan-designation/orphan-incentives>
12. Tadepalli M, Sri Veeravalli S and Reddy Juturi RK. *Comprehensive Review On Orphan Drug Regulations In The USA, EU, Japan, And Australia: Possible Recommendations To Specific Challenges*. *IJPSR*.2022; 13(2):688-06 doi: 10.13040/IJPSR.0975-8232.13(2).688-06